X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
3.320
-0.080 (-2.35%)
At close: Sep 11, 2026, 4:00 PM EDT
3.500
+0.180 (5.42%)
After-hours: Sep 11, 2026, 4:10 PM EDT
X4 Pharmaceuticals Employees
X4 Pharmaceuticals had 45 employees as of December 31, 2025. The number of employees decreased by 98 or -68.53% compared to the previous year.
Employees
45
Change (1Y)
-98
Growth (1Y)
-68.53%
Revenue / Employee
$352,156
Profits / Employee
-$2,003,067
Market Cap
329.17M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 45 | -98 | -68.53% |
| Dec 31, 2024 | 143 | 50 | 53.76% |
| Dec 31, 2023 | 93 | 23 | 32.86% |
| Dec 31, 2022 | 70 | -13 | -15.66% |
| Dec 31, 2021 | 83 | 11 | 15.28% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Abeona Therapeutics | 226 |
| Lyell Immunopharma | 161 |
| SAB Biotherapeutics | 86 |
| Orchestra BioMed Holdings | 86 |
| Agenus | 81 |
| Upstream Bio | 75 |
| Sionna Therapeutics | 59 |
| Vicore Pharma Holding AB | 46 |
XFOR News
- 1 day ago - X4 Pharmaceuticals Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 2 days ago - X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference - GlobeNewsWire
- 3 days ago - X4 Pharmaceuticals announces results from Type C Meeting with FDA - TheFly
- 3 days ago - X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting - GlobeNewsWire
- 10 days ago - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 16 days ago - X4 Pharmaceuticals treatment of congenital neutropenia gets orphan designation - TheFly
- 5 weeks ago - X4 Pharmaceuticals reports Q2 EPS (13c), consensus (18c) - TheFly
- 5 weeks ago - X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire